SOTYKTU (deucravacitinib)
Self-Administration – oral tablet
Indications for Prior Authorization:
Plaque Psoriasis (PsO): Indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Limitations of Use: Sotyktu is not recommended for use in combination with other potent immunosuppressants
Coverage Criteria:
For diagnosis of plaque psoriasis (PsO):
- Documented diagnosis of moderate to severe PsO; AND
- Prescribed by or in consultation with a dermatologist
- One of the following:
- Greater than or equal to 3% body surface area involvement
- Severe scalp psoriasis
- Palmoplantar (i.e., palms, soles), facial, or genital involvement; AND
- Minimum duration of a 4-week trial and failure, contraindication, or intolerance to one of the following topical therapies:
- corticosteroids (e.g., betamethasone, clobetasol)
- vitamin D analogs (e.g., calcitriol, calcipotriene)
- tazarotene
- calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
- anthralin
- coal tar; AND
- One of the following:
- Both of the following:
- Trial and failure, contraindication, or intolerance to THREE of the following:
- Cimzia (certolizumab pegol)
- Enbrel (etanercept)
- Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz
- Skyrizi (risankizumab)
- Stelara (ustekinumab)
- Tremfya (guselkumab)
- Trial and failure, contraindication, or intolerance to Taltz (ixekizumab)
- Trial and failure, contraindication, or intolerance to THREE of the following:
- For continuation of prior Sotyktu therapy, defined as no more than a 45-day gap in therapy.
- Both of the following:
Reauthorization Criteria:
For diagnosis of PsO:
- Documentation of positive clinical response to therapy as evidenced by one of the following:
- Reduction the body surface area (BSA) involvement from baseline
- Improvement in symptoms (e.g., pruritus, inflammation) from baseline
Dosing:
PsO (adults):
- 6 mg taken orally once daily.
Coverage Duration:
- Initial: 6 months
- Reauthorization: 1 year
Authorization is not covered for the following:
The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Additional Information:
Review History:
- 11/15/2022 – New drug UM policy approved by P&T.
- 09/01/2023 - Addition of Amjevita, Cyltezo, Hyrimoz, and brand Adalimumab-adaz as preferred options. (P&T 8/15/2023)
- 11/14/2023 – Update Hyrimoz preferred agent to Sandoz manufacturer only.
References:
- Sotuktu Prescribing Information. Bristol-Myers Squibb Co. Princeton, NJ. September 2022.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72.
- Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.
Last review date: November 14, 2023